Article Dans Une Revue European Respiratory Journal Année : 2021

Bronchial thermoplasty in patients with dynamic hyperinflation: results from the proof-of-concept HEAT trial

Résumé

Severe refractory asthma affects 3–5% of asthmatic patients, but represents 50–80% of asthma-related healthcare costs [1]. Although therapies targeting IgE and, more recently, IL5 and IL4/13 have recently gained approval for the treatment of severe refractory asthma in a subset of patients with type 2 phenotypes, there is still a need to cover a wider range of patients, in particular those with a non-type 2 phenotype or for whom biotherapies failed

Dates et versions

hal-03563909 , version 1 (10-02-2022)

Identifiants

Citer

Nicolas Guibert, Laurent Guilleminault, Benoit Lepage, Valentin Heluain, Romane Fumat, et al.. Bronchial thermoplasty in patients with dynamic hyperinflation: results from the proof-of-concept HEAT trial. European Respiratory Journal, 2021, 57 (1), pp.2001616. ⟨10.1183/13993003.01616-2020⟩. ⟨hal-03563909⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

More